Compare MPWR & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MPWR | REGN |
|---|---|---|
| Founded | 1997 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 66.5B | 77.5B |
| IPO Year | 2004 | 1995 |
| Metric | MPWR | REGN |
|---|---|---|
| Price | $1,543.64 | $749.36 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 14 | 25 |
| Target Price | ★ $1,137.21 | $827.76 |
| AVG Volume (30 Days) | 464.5K | ★ 525.9K |
| Earning Date | 04-30-2026 | 04-29-2026 |
| Dividend Yield | ★ 0.54% | 0.50% |
| EPS Growth | N/A | ★ 8.19 |
| EPS | 12.86 | ★ 41.48 |
| Revenue | $333,067,000.00 | ★ $5,872,227,000.00 |
| Revenue This Year | $23.89 | $12.45 |
| Revenue Next Year | $17.62 | $10.13 |
| P/E Ratio | $115.44 | ★ $18.04 |
| Revenue Growth | 17.89 | ★ 20.82 |
| 52 Week Low | $532.79 | $476.49 |
| 52 Week High | $1,492.50 | $821.11 |
| Indicator | MPWR | REGN |
|---|---|---|
| Relative Strength Index (RSI) | 80.36 | 46.75 |
| Support Level | $899.99 | $732.04 |
| Resistance Level | N/A | $787.20 |
| Average True Range (ATR) | 45.76 | 16.63 |
| MACD | 30.06 | -0.78 |
| Stochastic Oscillator | 95.07 | 32.09 |
Monolithic Power Systems is an analog and mixed-signal chipmaker specializing in power management solutions. Its mission is to reduce total energy consumption in end systems. It serves the computing, automotive, industrial, communications, and consumer end markets. MPS uses a fabless manufacturing model, partnering with third-party chip foundries to host its proprietary BCD process technology.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).